The Power of Prevention: The Untapped Potential of Adult Immunisation Programmes

By Staff Writer

January 1, 2024

The Unseen Value of Adult Immunisation

Adult immunisation programmes are often overlooked. But these are critical to addressing key health and societal challenges. A detailed review by the  Office of Health Economics (OHE) of these programmes has recently been conducted. Focusing on diseases such as seasonal influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus, reveals their crucial role in global health. The benefits of these programmes extend beyond health, impacting social care systems and aligning with global agendas such as the UN Sustainable Development Goals (SDGs) and the WHO Immunisation Agenda 2030 (IA2030). However, the full value of such programmes is often underestimated due to underrepresentation in academic literature, leading to suboptimal investment decisions.

The Rising Burden of Infectious Diseases and Ageing Populations

The world is witnessing significant demographic shifts, with ageing populations becoming a dominant trend. Infectious diseases like shingles and pneumococcal disease pose severe threats to older adults, leading to substantial hospitalisation burdens. Alongside this, the ‘tripledemic’ of COVID-19, seasonal influenza, and RSV, coupled with rising rates of chronic diseases among younger age groups, is exerting immense pressure on healthcare systems. This necessitates a shift from treatment to prevention, with vaccination standing as a fundamental preventive measure.

The Economic and Health Benefits of Adult Immunisation

Adult immunisation programmes are not just health measures, but also economically beneficial strategies. They are cost-effective and can result in net cost savings for healthcare systems. Recent studies in Australia and Germany underline that these programmes offer financial gains by averting hospital inpatient and emergency care. Expanding adult immunisation programmes and coverage can lead to substantial productivity gains and economic benefits for society. Moreover, these programmes can contribute to health and economic equity within countries, benefiting vulnerable and underserved communities.

The Urgent Need for Further Research and Adoption of a Preventive Mindset

Despite the clear benefits, significant gaps exist in evidence regarding the broader elements of the value of immunisation programmes. This calls for urgent research to prioritise and enhance adult immunisation programmes for the benefit of society and public health. It is vital for policy- and decision-makers to adopt a prevention-first mindset and implement robust adult immunisation programmes that are proven cost-effective. Expanding the evidence base for the broader value of adult immunisation is a crucial step towards optimising the value of these programmes.

Conclusion: The Power of Prevention

Adult immunisation programmes are powerful tools in the fight against infectious diseases and the burden they place on healthcare systems. They are cost-effective, promote health equity, and align with global health goals. However, their full potential remains untapped, largely due to underrepresentation in academic literature and a lack of awareness among decision-makers. It’s time to shift our focus from treatment to prevention and recognise the immense value that adult immunisation programmes bring to society.

Reference url

Recent Posts

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

NICE HealthTech Reforms
            

NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global Healthcare Systems

🌐 Are you ready to witness a paradigm shift in digital health technology?

The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.

Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!

#SyenzaNews #DigitalHealth #HealthEconomics #Innovation

BioNTech BMS collaboration
   

BioNTech BMS Collaboration: Pioneering Advances in Solid Tumor Treatment with BNT327

🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?

Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.

Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!

#SyenzaNews #oncology #drugdevelopment #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.